GlobeNewswire: Industry News on Biotechnology Contains the last 10 of 88406 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:09:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2854074/0/en/Mustang-Bio-Announces-Vision-for-CAR-T-Cell-Therapy-Platform-Expansion-into-Autoimmune-Diseases.html?f=22&fvtc=3&fvtv=4573Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases2024-03-28T13:00:51Z<![CDATA[Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024]]>https://www.globenewswire.com/news-release/2024/03/28/2854066/0/en/T2-Biosystems-Announces-Extension-of-Multi-Year-Capital-Equipment-Supplier-Agreement-with-Vizient-Inc.html?f=22&fvtc=3&fvtv=4573T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.2024-03-28T13:00:00Z<![CDATA[LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2025. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.]]>https://www.globenewswire.com/news-release/2024/03/28/2853993/0/en/TransCode-Therapeutics-Announces-Appointment-of-Daniel-Vlock-M-D-as-Chief-Medical-Officer.html?f=22&fvtc=3&fvtv=4573TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer2024-03-28T12:30:00Z<![CDATA[Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy]]>https://www.globenewswire.com/news-release/2024/03/28/2853995/0/en/Third-Harmonic-Bio-Appoints-Geoff-McDonough-M-D-to-its-Board-of-Directors.html?f=22&fvtc=3&fvtv=4573Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors2024-03-28T12:30:00Z<![CDATA[SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.]]>https://www.globenewswire.com/news-release/2024/03/28/2853996/0/en/CervoMed-Announces-Up-to-149-4-Million-Private-Placement-Financing-Joined-by-Leading-Healthcare-Investors.html?f=22&fvtc=3&fvtv=4573CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors2024-03-28T12:30:00Z<![CDATA[Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital]]>https://www.globenewswire.com/news-release/2024/03/28/2854006/0/en/Dyadic-Announces-Change-in-Board-and-Management-Leadership-Roles.html?f=22&fvtc=3&fvtv=4573Dyadic Announces Change in Board and Management Leadership Roles2024-03-28T12:30:00Z<![CDATA[JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that Michael Tarnok is stepping down as Chairman of Dyadic’s board of directors (the “Board”) and that current member of the Board Patrick Lucy has been appointed to succeed him, in each case, effective immediately. Mr. Tarnok will continue to serve as a director through the end of his current term, which will end at the Company’s annual meeting in June 2025, at which time he expects to retire. In addition, Dr. Barry Buckland announced that he is retiring and therefore will not stand for re-election at the Company’s annual meeting in June 2024. The Board has decided not to fill the vacancy due to Dr. Buckland’s retirement which will result in a reduction of the size of the Board from seven to six members. Finally, Joseph Hazelton has been appointed Chief Operating Officer, effective immediately, and will oversee the day-to-day operations of the Company.]]>https://www.globenewswire.com/news-release/2024/03/28/2854007/0/en/Tenax-Therapeutics-Provides-Business-and-Clinical-Development-Updates-with-Full-Year-2023-Financial-Results.html?f=22&fvtc=3&fvtv=4573Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results2024-03-28T12:30:00Z<![CDATA[CHAPEL HILL, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced full year 2023 financial results, and provided clinical development and business updates.]]>https://www.globenewswire.com/news-release/2024/03/28/2853981/0/en/Biomerica-InFoods-IBS-Data-to-be-Presented-at-the-Upcoming-Digestive-Disease-Week-DDW-2024-Conference.html?f=22&fvtc=3&fvtv=4573Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference2024-03-28T12:19:00Z<![CDATA[IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC. DDW is renowned as the world's premier scientific and clinical meeting for digestive disease health care professionals.]]>https://www.globenewswire.com/news-release/2024/03/28/2853970/0/en/Candel-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Corporate-Highlights.html?f=22&fvtc=3&fvtv=4573Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights2024-03-28T12:05:47Z<![CDATA[NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2024/03/28/2853967/0/en/Tevogen-Bio-Reports-Series-A-1-Preferred-Stock-Investment-at-10-Conversion-Price.html?f=22&fvtc=3&fvtv=4573Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price2024-03-28T12:05:00Z<![CDATA[WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.]]>